Kaouthar Lbiati, MD
Interim Chief Executive Officer
Dr. Lbiati brings over 15 years of global leadership experience in both biotech and large pharmaceutical companies. She also serves on the board of Theralase Technologies Inc., a publicly traded, clinical-stage oncology company. Throughout her career, Dr. Lbiati has played pivotal roles in advancing innovative therapies from preclinical development to global commercialization across a wide range of therapy areas including regenerative medicine. She has led cross-functional teams, built strategic partnerships, secured regulatory approvals and reimbursement in diverse international markets, and successfully contributed to the launch of breakthrough treatments including Jevtana® , Votrient® , Blincyto® , Filgotinib® , and Symbicort® , across oncology, hematology, immune-inflammation, respiratory diseases, respectively. Learn more >>